IL-23 and IL-27 levels in macrophages collected from peripheral blood of patients with healing vs non-healing form of cutaneous leishmaniasis

Iranian Journal of Parasitology

Volumn 7, Issue 1, 2012, Pages 18-25

  Tolouei, S ^a   Ghaedi, K ^b,c   Khamesipour, A ^d   Akbari, M ^a   Baghaei, M ^e   Hasheminia, S J ^a   Narimani, M ^a   Hejazi, S H ^f  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ISFAHAN   (Iran)

^c ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISLAMIC AZAD UNIVERSITY   (Iran)

^f ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; IL 23; IL 27; Macrophages; Promastigote

Indexed keywords

INTERLEUKIN 23; INTERLEUKIN 27; MEGLUMINE ANTIMONATE;

ADULT; AGED; ARTICLE; CELL LEVEL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALING; HUMAN; IN VITRO STUDY; LEISHMANIA MAJOR; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERIPHERAL CIRCULATION; PROMASTIGOTE; SKIN DEFECT; SKIN LEISHMANIASIS; SUPERNATANT;

LEISHMANIA MAJOR;

EID: 84860604193     PISSN: 17357020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol. 1996;14 (5):425-431.
2. Herwaldt BL. Leishmaniasis. Lancet. 1999 2;354(9185):1191-9.
3. Salman SM, Rubeiz NG, Kibbi AG. Cutaneous leishmaniasis: clinical features and diagnosis. Clin Dermatol. 1999: 17(3):291-296.
4. Lohoff M, Gessner A, Bogdan C, Rollinghoff M. Experimental murine leishmaniasis and the Th1/Th2 cell concept. Tokai J Exp Clin Med. 1998;23(6):347-350.
5. Milon G, Del Giudice G, Louis JA. Immunobiology of experimental cutaneous leishmaniasis. Parasitol Today. 1995; 11(7):244-247.
6. Muller I, Fruth U, Louis JA. Immunobiology of experimental leishmaniasis. Med Microbiol Immunol. 1992;181(1):1-12.
7. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2(11):845-858.
8. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun. 2000;68 (4):1760-17664.
9. Ajdary S, Jafari-Shakib R, Riazi-Rad F, Khamesipour A. Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis. J Infect. 2007;55(1):75-78.
10. Habibi GR, Khamesipour A, McMaster WR, Mahboudi F. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semiquantitative RT-PCR. Scand J Immunol. 2001;54(4):414-420.
11. Mahmoodi M, Rajabalian S, Fekri A, Esfandiarpour I. Evaluation of in vitro production of ifn-gamma, il-10, il-12 and il-13 by blood cells in patients with cutaneous leishmaniasis lesions. Iran J Allergy Asthma Immunol. 2005;4(1):15-21.
12. Jafari-Shakib R, Shokrgozar MA, Nassiri- Kashani M et al. Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis. Acta Trop. 2009;109(1):61-63.
13. Bogdan C, Gessner A, Rollinghoff M. Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology. 1993;189(3-4):356-396.
14. Cutler A, Brombacher F. Cytokine therapy. Ann N Y Acad Sci. 2005 Nov;1056:16-29.
15. Calandra T, Bochud PY, Heumann D. Cytokines in septic shock. Curr Clin Top Infect Dis. 2002;22:1-23.
16. Santamaria P. Cytokines and chemokines in autoimmune disease: an overview. Adv Exp Med Biol. 2003;520:1-7.
17. Hunter CA, Villarino A, Artis D, Scott P. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol Rev. 2004;202:106-114.
18. Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin-23: immunological roles and clinical implications. Int J Biochem Cell Biol. 2009;41(4):733-735.
19. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13(5):715-725.
20. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 (+) T cells. Immunity. 2002;16(6):779-790.
21. Yoshida H, Miyazaki Y. Regulation of immune responses by interleukin-27. Immunol Rev. 2008;226:234-247.
22. Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol. 2007;179(7):4415-4423.
23. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139-156.
24. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89.
25. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006;123(3):423-438.
26. Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz). 2006;54(1):15-24.
27. Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther. 2005;7(1):12-19.
28. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511.
29. Romagnani S. Regulation of the T cell response. Clin Exp Allergy. 2006;36(11):1357-1366.
30. Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett. 2002;209(1):1-7.
31. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. 2001;15(4):569-578.
32. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity. 2003; 19(5):645-655.
33. Lieberman LA, Cardillo F, Owyang AM, Rennick DM, Cua DJ, Kastelein RA, et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol. 2004;173(3):1887-1893.
34. Kullberg MC, Jankovic D, Feng CG et al. IL- 23 plays a key role in Helicobacter hepaticusinduced T cell-dependent colitis. J Exp Med. 2006;203(11):2485-2494.
35. Smits HH, van Beelen AJ, Hessle C et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol. 2004; 34(5):1371-1380.